Search company, investor...

Compare Aqumen Biopharmaceuticals vs Inflabloc Pharmaceuticals

Customers evaluate the quality of Aqumen Biopharmaceuticals's products using the following success metrics.

Overview

Aqumen Biopharmaceuticals is based in Japan

The company's current portfolio of compounds and technologies in the development pipeline includes: i) A0001, Ophthalmic Dye for Retinal Surgery ii) A0003, treatments for Age-related Macular Degeneration (AMD). and iii)A0006 . Company is in negotiations to acquire rights to a Phase II program by year end 2007. The following diagram summarizes the important existing and anticipated clinical development milestones for each of the programs as they relate to their respective targeted applications:

Inflabloc Pharmaceuticals is 33 yrs old and is based in United States.

Inflabloc Pharmaceuticals, Inc. is engaged in the research and development of pharmaceutical treatments for inflammatory disorders. Inflabloc's current product development is based on its discoveries of strong anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. The company's lead product line is a DHEA combination treatment. The company has 4 products in development. IP-1001 is slated to enter Phase 2 clinical trials in Crohn's disease later this year. IP-1002 has completed Phase 1. IP-1003 recently established proof-of-concept in an inflammatory bowel disease (IBD) animal model, while IP-1005 has just entered proof-of-concept testing in a C-reactive protein (CRP) mouse model.

Demo Video

Demo not available because Aqumen Biopharmaceuticals has not claimed their profile.

Work for Aqumen Biopharmaceuticals? Show off your product.

Demo not available because Inflabloc Pharmaceuticals has not claimed their profile.

Work for Inflabloc Pharmaceuticals? Show off your product.

Leadership

Willem Spiegel (Chief Financial Officer)

See all 5 people

Funding

Inflabloc Pharmaceuticals last raised $6M on 2/13/2006.

Investors

Mitsubishi UFJ Capital

vSpring Capital, Friedli Corporate Finance

See all 5 investors

Product

Benefits

Products

Customers

Known Partners

Why They Buy

Information not available because Aqumen Biopharmaceuticals has not claimed their profile.

Work for Aqumen Biopharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Aqumen Biopharmaceuticals?

Claim your profile now.

Information not available because Inflabloc Pharmaceuticals has not claimed their profile.

Work for Inflabloc Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Inflabloc Pharmaceuticals?

Claim your profile now.